A Guide for Talking with Your Doctor About PNH and Soliris®

Your healthcare team is there for you. Feel free to openly discuss with your team any questions or concerns you may have. We’ve put together a list of some questions and points to consider to help guide your conversations.

Questions to consider

  • What should I know about PNH?
  • Is reducing hemolysis the primary goal of PNH management?
  • What are my treatment options?
    • What are the benefits of these treatments?
    • What are the risks of these treatments?
  • What are the benefits of treatment with Soliris?
  • What are the risks of treatment with Soliris?
  • What do you do to monitor my PNH?

Points to bring up

  • Make sure your doctor knows about any other drugs you may be taking
  • It’s important that your doctor takes into consideration other conditions you may have, including aplastic anemia (AA) or myelodysplastic syndromes (MDS)
  • Inform your doctor of any allergies to medications you may have
  • Openly discuss availability for infusion appointments



IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.

This site is intended for US audiences only. © Copyright and Terms of Use 1999 - 2010 Alexion Pharmaceuticals. All rights reserved. Site Map | Privacy Policy | Legal | Glossary
SOLUS03-0095-001